The effect of adding pyridostigmine to second generation antipsychotic drugs on schizophrenia symptoms: A double blind randomised placebo controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015041521779N1

Enrollment

Registered

2015-10-28

Start date

2015-06-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. The schizophrenic disorders are characterized in general by fundamental and characteristic distortions of thinking and perception, and affects that are inappropriate or blunted. Clear consciousness and intellectual capacity are usually maintained although

Interventions

Intervention 1: Interventional group:this group that include 15 schizophrenic patients are selected quite rondom and treated with 2 generation antipsychotic drugs , pyridostigmine tablet 60 mg wil

Treatment - Drugs

Interventional group:this group that include 15 schizophrenic patients are selected quite rondom and treated with 2 generation antipsychotic drugs , pyridostigmine tablet 60 mg will add to main tr

In placebo group that include 15 schizophrenic patients are selected rondom and treated with 2 generation antipsychotic drugs, placebo tablet that is quite similar to pyridostigmine tablet will add

Eligibility

Sex/Gender

All

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: The main inclusion criteria is having schizophrenia disorder.inclusion criteria: The average age between 20 to 40 years and knowing persian language and having consent of participation in this research and having no brain organic disease and using no any anti depressants such as tricyclics drugs and donepezi drug. Exclusion criteria :demensia and severe organic disease and very old age and young age and other neurologic diseases that patients must use anticholinesterase drugs and use of tricyclic antidepressants and donepezil drug.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Schizophrenic Disorder Symptom. Timepoint: In First And End Of 4 Weeks Of Research. Method of measurement: By Using Panss And Bprs Scales.	—

Secondary

Measure	Time frame
Comparsion between complications of adding pyridostigmine with 2 generation antipsycotic drugs versus complications of antipsychotics alone. Timepoint: Along of research. Method of measurement: With recurrent visit of patients.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Pakseresht Syrous

Jondi Shapour University of Medical Sciences of Ahvaz

paks392003@yahoo.com+98 61337430025

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026